Abstract
A new study by Lo et al. presents a novel immunosuppressive combination in a clinically relevant primate model of renal allografting. Using belatacept, a fusion protein that inhibits CD28–CD80/CD86 co-stimulation, plus the mammalian target of rapamycin inhibitor sirolimus, they were able to achieve rejection-free allograft survival without the induction of memory T cells or alloantibody.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have